Dr. Reddy's launches first-to-market Bosutinib 400mg generic in the United States

What Dr. Reddy's announced

On 13 June 2026 Dr. Reddy's Laboratories Limited filed a press release with the National Stock Exchange stating that it has launched Bosutinib Tablets 400 mg in the United States. The product is a generic equivalent of Bosulif®, a branded therapy used in the treatment of chronic myeloid leukaemia (CML). The company describes the launch as first‑to‑market for this specific dosage form in the U.S. market.

"Dr. Reddy's announces the first‑to‑market launch of Bosutinib Tablets 400 mg, a generic equivalent of Bosulif®, in the United States."

Product details

• Active ingredient: Bosutinib, a tyrosine‑kinase inhibitor.
• Dosage form: Tablet, 400 mg strength.
• Therapeutic area: Oncology – specifically chronic myeloid leukaemia.
• Regulatory status: The filing does not specify FDA approval dates or the regulatory pathway used, only that the product is now available in the U.S. market.

Regulatory and market context

The filing does not provide details on the regulatory submission (e.g., ANDA) or any exclusivity periods. It also does not disclose pricing, expected launch volume, or projected revenue contribution. The announcement is limited to the fact of launch and the positioning as a first‑to‑market generic.

Key facts at a glance

Why this matters for investors

The launch adds a new oncology generic to Dr. Reddy's portfolio, potentially expanding its presence in the high‑value U.S. oncology market. Being first‑to‑market may give the company a temporary competitive edge before other generics enter. However, the filing does not disclose any financial impact, pricing strategy, or expected sales, so investors cannot quantify the contribution to revenue or earnings at this stage.

Conclusion

Dr. Reddy's Laboratories has formally announced the U.S. launch of Bosutinib 400 mg tablets, marking the first generic entry for Bosulif® in that market. While the move broadens the company's oncology pipeline, the filing provides no quantitative details on pricing, volume or revenue impact, leaving the financial significance to be clarified in future disclosures.